Exagen Inc. (XGN) stock
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.90+0.14 (+3.72%)
Close on Nov 18, 2026Market cap $94.48MP/E –Yield –
Exagen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Exagen's revenue for the twelve months ending Jun 30, 2026 was $71.12M, up 20.8% year over year. For fiscal 2025 it was $66.58M, up 19.7% from the year before. The highest annual figure on record is $66.58M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.58M | +19.7% |
| FY2024 | Dec 31, 2024 | $55.64M | +5.9% |
| FY2023 | Dec 31, 2023 | $52.55M | +15.3% |
| FY2022 | Dec 31, 2022 | $45.56M | -5.7% |
| FY2021 | Dec 31, 2021 | $48.30M | +15.1% |
| FY2020 | Dec 31, 2020 | $41.98M | +3.9% |
| FY2019 | Dec 31, 2019 | $40.39M | +24.5% |
| FY2018 | Dec 31, 2018 | $32.44M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.94M | +15.9% |
| Q1 FY2026 | Mar 31, 2026 | $17.31M | +11.7% |
| Q4 FY2025 | Dec 31, 2025 | $16.63M | +21.8% |
| Q3 FY2025 | Sep 30, 2025 | $17.24M | +37.9% |
| Q2 FY2025 | Jun 30, 2025 | $17.20M | +14.2% |
| Q1 FY2025 | Mar 31, 2025 | $15.50M | +7.5% |
| Q4 FY2024 | Dec 31, 2024 | $13.66M | -0.8% |
| Q3 FY2024 | Sep 30, 2024 | $12.51M | -6.8% |
| Q2 FY2024 | Jun 30, 2024 | $15.06M | +6.6% |
| Q1 FY2024 | Mar 31, 2024 | $14.42M | +28.4% |
| Q4 FY2023 | Dec 31, 2023 | $13.77M | +7.2% |
| Q3 FY2023 | Sep 30, 2023 | $13.42M | -8.9% |
| Q2 FY2023 | Jun 30, 2023 | $14.14M | +85.9% |
| Q1 FY2023 | Mar 31, 2023 | $11.23M | +8.0% |
| Q4 FY2022 | Dec 31, 2022 | $12.84M | +1.2% |
| Q3 FY2022 | Sep 30, 2022 | $14.73M | +20.2% |
| Q2 FY2022 | Jun 30, 2022 | $7.61M | -40.4% |
| Q1 FY2022 | Mar 31, 2022 | $10.39M | -1.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.69M | +0.2% |
| Q3 FY2021 | Sep 30, 2021 | $12.25M | +13.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.77M | +42.7% |
| Q1 FY2021 | Mar 31, 2021 | $10.59M | +10.5% |
| Q4 FY2020 | Dec 31, 2020 | $12.67M | +24.0% |
| Q3 FY2020 | Sep 30, 2020 | $10.78M | +3.2% |
| Q2 FY2020 | Jun 30, 2020 | $8.95M | -14.6% |
| Q1 FY2020 | Mar 31, 2020 | $9.58M | +3.5% |
| Q4 FY2019 | Dec 31, 2019 | $10.21M | +5.9% |
| Q3 FY2019 | Sep 30, 2019 | $10.44M | +26.9% |
| Q2 FY2019 | Jun 30, 2019 | $10.47M | – |
| Q1 FY2019 | Mar 31, 2019 | $9.26M | – |
| Q4 FY2018 | Dec 31, 2018 | $9.64M | – |
| Q3 FY2018 | Sep 30, 2018 | $8.22M | – |
See a number that looks wrong?